Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100196 | 0.95 | PTGS2 (0.46) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100108 | 0.89 | PTGS2 (0.48) | MAPTPTGS2CA1CA2CA12 | |
| SCHEMBL13100115 | 0.86 | PTGS2 (0.45) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100109 | 0.85 | PTGS2 (0.44) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100078 | 0.85 | PTGS2 (0.44) | GAAHPGDPTGS2CA1CA2 | |
| SCHEMBL13100062 | 0.85 | PTGS2 (0.46) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100203 | 0.84 | PTGS2 (0.48) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL13100086 | 0.84 | PTGS2 (0.43) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100104 | 0.84 | PTGS2 (0.45) | PTGS2CA1CA2CA12CA4 | |
| SCHEMBL13100107 | 0.84 | PTGS2 (0.44) | SMN1; SMN2PTGS2CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | MAPT 4236/4885ALDH1A1 1198/4885LMNA 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.